Abstract
AbstractStarting Parkinson’s disease (PD) patients on subcutaneous apomorphine (APO) infusion is generally undertaken on a hospital day-case basis. During the COVID-19 pandemic, day-case facilities were unavailable. To avoid delays in treatment, a new procedure was developed for initiation of APO therapy in the patient’s home. A home initiation protocol was developed and followed for each patient in this analysis. The hospital team worked in collaboration with APO nurses provided by the manufacturer of APO therapies to implement initiation and undertake follow-up. In this analysis, 27 PD patients were initiated onto APO infusion and 21 (77.8%) achieved a therapeutic response. Home initiation of APO infusion can be undertaken successfully and has benefits for both patients and healthcare teams. This protocol will now continue as a standard of care at our centre.
Publisher
Springer Science and Business Media LLC
Subject
Biological Psychiatry,Psychiatry and Mental health,Neurology (clinical),Neurology
Reference13 articles.
1. APO-go PFS 5mg/ml Solution for Infusion in Pre-filled Syringe (2018). EU Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/medicine/15992.
2. European Medicines Agency (2014) PRAC recommends restricting use of domperidone, available at: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Domperidone_31/Recommendation_provided_by_Pharmacovigilance_Risk_Assessment_Committee/WC500162559.pdf.
3. Fasano A, Antonini A, Katzenschlager R, Krack P, Odin P, Evans AH, Foltynie T, Volkmann J, Merello M (2020) Management of advanced therapies in Parkinson’s disease patients in times of humanitarian crisis: the COVID-19 experience. Mov Disord Clin Pract 7(4):361–372
4. Griffiths RI, Kotschet K, Arfon S, Xu ZM, Johnson W, Drago J, Evans A, Kempster P, Raghav S, Horne MK (2012) Automated assessment of bradykinesia and dyskinesia in Parkinson’s disease. J Parkinsons Dis 2(1):47–55
5. Jenner P, Katzenschlager R (2016) Apomorphine—pharmacological properties and clinical trials in Parkinson’s disease. Parkinsonism Related Disord 33(Suppl 1):S13–S21